Inflammatory bowel disease associated arthropathy

Current Reviews in Musculoskeletal Medicine

Volumn 4, Issue 3, 2011, Pages 123-131

  Arvikar, Sheila L ^a   Fisher, Mark C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Arthritis; Biologics; Crohn's disease; DMARDS; Extraintestinal manifestations; IBD; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ABATACEPT; ADALIMUMAB; ANALGESIC AGENT; C REACTIVE PROTEIN; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTHROPATHY; ARTICLE; BONE DENSITY; CLINICAL FEATURE; CROHN DISEASE; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; ENTERITIS; ENTEROPATHY; ERYTHROCYTE SEDIMENTATION RATE; GENETIC SUSCEPTIBILITY; HLA TYPING; HUMAN; INTESTINE SURGERY; JOINT RADIOGRAPHY; LEUKOCYTE COUNT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL ARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; THROMBOCYTE COUNT; ULCERATIVE COLITIS;

EID: 80055003404     PISSN: 1935973X     EISSN: 19359748     Source Type: Journal    
DOI: 10.1007/s12178-011-9085-8     Document Type: Article

References (98)

1. Salvarani C, Vlachonikolis IG, van der Heijde DM, et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36:1307-13. (Pubitemid 33027811)
2. Lanna CC, Ferrari Mde L, Rocha SL, et al. A cross-sectional study of 130 Brazilian patients with Crohn's disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol. 2008;27:503-9.
3. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218-27.
4. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387-91. (Pubitemid 28197029)
5. Calin A, Porta J, Fries J, Schurman D. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977;237:2613-4. (Pubitemid 8104225)
6. Sieper J, van der Heijde D, Landewé R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from theAssessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis. 2009;68:784-8.
7. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-8. (Pubitemid 14134775)
8. McEniff N, Eustace S, McCarthy C, et al. Asymptomatic sacroiliitis in inflammatory bowel disease. Assessment by computed tomography. Clin Imaging. 1995;19:258-62.
9. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol. 2004;31:695-700. (Pubitemid 38451254)
10. Naranjo A, Ojeda S, Erausquin C, et al. Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability. Ann Rheum Dis. 2002;61:660-1. (Pubitemid 34717789)
11. Almodóvar R, Carmona L, Zarco P, et al. Fibromyalgia in patients with ankylosing spondylitis: prevalence and utility of the measures of activity, function and radiological damage. Clin Exp Rheumatol. 2010;28:S33-9.
12. Palm O, Moum B, Jahnsen J, Gran JT. Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: a cross sectional population survey. J Rheum. 2001;28:590-4. (Pubitemid 32202665)
13. Buskila D, Odes LR, Neumann L, Odes HS. Fibromyalgia in inflammatory bowel disease. J Rheum. 1999;26:1167-71. (Pubitemid 29215085)
14. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-17.
15. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424-9. (Pubitemid 350181588)
16. Acheson ED. An association between ulcerative colitis, regional enteritis, and ankylosing spondylitis. Q J Med. 1960;29:489-99.
17. Ansell BM, Wigley RA. Arthritic manifestations in regional enteritis. Ann Rheum Dis. 1964;23:64-72.
18. Wright V, Watkinson G. Sacro-iliitis and ulcerative colitis. Br Med J. 1965;2:675-80.
19. Wright V, Watkinson G. The arthritis of ulcerative colitis. Br Med J. 1965;2:670-5.
20. Haslock I. Arthritis and Crohn's disease. A family study. Ann Rheum Dis. 1973;32:479-86.
21. Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, et al. Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis. 1978;37:33-5. (Pubitemid 8371820)
22. Maeda K, Okada M, Yao T, et al. Intestinal and extraintestinal complications of Crohn's disease: predictors and cumulative probability of complications. J Gastroenterol. 1994;29:577-82. (Pubitemid 24308405)
23. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29-34. (Pubitemid 26244497)
24. Suh CH, Lee CH, Lee J, et al. Arthritic manifestations of inflammatory bowel disease. J Korean Med Sci. 1998;13:39-43. (Pubitemid 128686790)
25. Triantafillidis JK, Emmanouilidis A, Manousos O, Nicolakis D, Kogevinas M. Clinical patterns of Crohn's disease in Greece: a follow-up study of 155 cases. Digestion. 2000;61:121-8. (Pubitemid 30114079)
26. de Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000;27:2860-5.
27. Queiro R, Maiz O, Intxausti J, et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clin Rheumatol. 2000;19:445-9. (Pubitemid 32041012)
28. Christodoulou DK, Katsanos KH, Kitsanou M, et al. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig Liver Dis. 2002;34:781-6. (Pubitemid 36097517)
29. Palm ø, Moum B, Jahnsen J, Gran JT. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford). 2001;40:1256-61.
30. Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol. 2002;29:511-5. (Pubitemid 34202820)
31. Al-Shamali MA, Kalaoui M, Patty I, et al. Ulcerative colitis in Kuwait: a review of 90 cases. Digestion. 2003;67:218-24. (Pubitemid 37100202)
32. Steer S, Jones H, Hibbert J, et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol. 2003;30:518-22. (Pubitemid 36301944)
33. Turkcapar N, Toruner M, Soykan I, et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int. 2006;26:663-8.
34. Peeters H, Vander Cruyssen B, Mielants H, et al. Clinical and genetic factors associated with sacroiliitis in Crohn's disease. J Gastroenterol Hepatol. 2008;23:132-7. (Pubitemid 350265198)
35. Orchard TR, Holt H, Bradbury L, et al. The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn's disease. Aliment Pharmacol Ther. 2008;29:193-7.
36. D'Incà R, Podswiadek M, Ferronato A, et al. Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig Liver Dis. 2009;41:565-9.
37. Yüksel I, Ataseven H, Başar O, et al. Peripheral arthritis in the course of inflammatory bowel disease. Dig Dis Sci. 2011;56:183-7.
38. Hwangbo Y, Kim HJ, Park JS, et al. Sacroiliitis is common in Crohn's disease patients with perianal or upper gastrointestinal involvement. Gut Liver. 2010;4:338-44.
39. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110-9. This is a recent epidemiologic study examining EIMs in a large cohort of IBD patients.
40. Mielants H, Veys EM, Cuvelier C, De Vos M. Subclinical involvement of the gut in undifferentiated spondylarthropathies. Clin Exp Rheumatol. 1989;7:499-504. (Pubitemid 20069360)
41. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology. 1996;110:1696-703. (Pubitemid 26169205)
42. Jacques P, Elewaut D. Joint expedition: linking gut inflammation to arthritis. Mucosal Immunol. 2008;1:364-71.
43. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359-64. (Pubitemid 24351619)
44. Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol. 2001;166:4650-7. (Pubitemid 32233752)
45. May E, Märker-Hermann E, Wittig BM, et al. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology. 2000;119:1745-55. (Pubitemid 32198700)
46. Demetter P, De Vos M, Van Huysse JA, et al. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis. 2005;64:321-4. (Pubitemid 40193638)
47. Baeten D, Demetter P, Cuvelier CA, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol. 2002;196:343-50. (Pubitemid 34189425)
48. Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocytesubtype specific adhesion. J Clin Invest. 1997;99:2165-72. (Pubitemid 27203772)
49. Armaka M, Apostolaki M, Jacques P, et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med. 2008;205:331-7. (Pubitemid 351281599)
50. Turner MJ, Soweders DP, DeLay ML, et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J Immunol. 2005;175:2438-48. (Pubitemid 41113854)
51. Reveille JD. The genetic basis of spondyloarthritis. Ann Rheum Dis. 2011;70:i44-50. This is an excellent review of the genetic associations of spondylarthropathies found to date.
52. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001;357:1925-8. (Pubitemid 32568333)
53. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603. (Pubitemid 32531408)
54. Ogura Y, Bonen DK, Inohara M, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-6. (Pubitemid 32531409)
55. Crane AM, Bradbury L, van Heel DA, et al. Role of NOD2 variants in spondylarthritis. Arthritis Rheum. 2003;46:1629-33. (Pubitemid 34620211)
56. Laukens D, Peeters H, Marichal D, et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis. 2005;64:930-5. (Pubitemid 40733921)
57. Miceli-Richard C, Zouali H, Lesage S, et al. CARD15/NOD2 analyses in spondylarthropathy. Arthritis Rheum. 2002;46:1405-6. (Pubitemid 34525851)
58. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461-3. (Pubitemid 44871953)
59. Rahman P, Inman RD, Gladman DD, et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum. 2008;58:1020-5. (Pubitemid 351564003)
60. Danoy P, Pryce K, Hadler J, Bradbury LA, Farrar C, Pointon J, et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet. 2010;6:e1001195. This a recent study identifying novel genetic susceptibility loci associated with AS and CD.
61. Brown M, Pile K, Kennedy L, et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis. 1996;55:268-70. (Pubitemid 26120706)
62. Enlow RW, Bias WB, Arnett FC. The spondylitis of inflammatory bowel disease. Evidence for a non-HLA linked axial arthropathy. Arthritis Rheum. 1980;23:1359-65. (Pubitemid 11199875)
63. Braun J, Baraliakos X. Imaging of axial spondyloarthritis including ankylosing spondylitis. Ann Rheum Dis. 2011;70:i97-103 This is an exellent review of imaging in axial SpA.
64. Baraliakos X, Listing J, Rudwaleit M, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007;66:910-5. (Pubitemid 46999792)
65. Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis. 2009;68:1520. This article defines a new approach for classifying SpA which includes MRI findings.
66. Abi Karam G, Awada H, Nasr F, Uthman I. Ileal pouchitis and arthritis. Semin Arthritis Rheum. 2003;33:215. (Pubitemid 38030083)
67. Balbir-Gurman A, Schapira D, Nahir M. Arthritis related to ileal pouchitis following total proctocolectomy for ulcerative colitis. Semin Arthritis Rheum. 2001;30:242-8. (Pubitemid 32172729)
68. Andreyev HJ, Kamm MA, Forbes A, Nicholls RJ. Joint symptoms after restorative proctocolectomy in ulcerative colitis and familial polyposis coli. J Clin Gastroenterol. 1996;23:35-9. (Pubitemid 26244498)
69. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4:203-11. (Pubitemid 43199691)
70. Carbonnel F. Methotrexate: a drug of the future in ulcerative colitis? Curr Drug Targets. 2011;e-pub, in press.
71. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340 (18):1398-405. (Pubitemid 29205403)
72. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 2002;359:1541.9. (Pubitemid 34621118)
73. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250-60.
74. Van den Bosch F, Kruithof E, Vos MD, Keyser FD, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet. 2000;356:1821-2.
75. Herfarth H, Obermeier F, Andus T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol. 2002;97:2688-90.
76. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004;63:1664-9. (Pubitemid 39573700)
77. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136-46. (Pubitemid 44051069)
78. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-9. (Pubitemid 47300424)
79. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65. (Pubitemid 46108762)
80. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32:1228-39.
81. ..Lofberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE. Inflamm Bowel Dis. 2011; epub ahead of print, doi: 10.1002/ibd.21663. This is a recent large multicenter open label trial assessing treatment of arthritis in IBD with Adalimumab.
82. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-94. (Pubitemid 33022088)
83. van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with Etanercept. J Rheumatol. 2011;epub ahead of print, doi: 10.3899/jrheum.100809
84. . Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-98. An important article which highlights the important issue of developing refractoriness to biologic therapies.
85. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135:1130-41.
86. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trail. Lancet. 2009;373:633-40.
87. Chen Z, Brant SR, Li C, et al. CTLA4.1661A/G and 3'UTR long repeat polymorphisms are associated with ulcerative colitis and influence CTLA4 mRNA and protein expression. Genes Immun. 2010;11:573-83.
88. Hradsky O, Dusatkova P, Lenicek M, et al. The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn's disease. BMC Med Genet. 2010;11:91.
89. Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010;126:e243-6. doi:10.1542/ peds.2009.3395.
90. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007;13:1365-8. (Pubitemid 350206846)
91. Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut. 2011;epub ahead of print: doi:10.1136/gut.2010.225482
92. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222-32.
93. Tebbutt NC, Giraud AS, Inglese M, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med. 2002;8:1089-97. (Pubitemid 35175963)
94. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology. 2007;132:1672-83. (Pubitemid 46695722)
95. . Etzel JP, Larson MF, Anawalt BD, Collins J, Dominitz JA. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis. 2011;Jan 13. This is an article highlighting the high prevalence of osteoporosis in IBD patients, and the underutilization of osteoporosis screening and treatment in IBD.
96. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2004;38:502-8.
97. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994;344:1125-1127. (Pubitemid 24317633)
98. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739-45.